Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

Mr. Li  Li

Co-Founder, Chairman of the Board & President

Ms. Juan  Chen

Vice President of Finance, Chief Financial Officer & Financial Controller

Mr. Fengqi  Qian

Joint Company Secretary

Ms. Tao  Han M.B.A.

Chief Business Officer

Ms. Sze Ting  Chan A.C.S.

Mr. Yu  Shan

Co-Founder, GM, Group Vice President & Executive Director

Ms. Tan  Li

Vice President, Deputy GM & Director

Mr. Ping  Zhang

Senior Vice President of Global Industrial Affairs

Mr. Xi  Gao

Senior Vice President of Global Supply Chain

名称	市场容量
China Medical System Holdings Limited	0M
TILT Holdings Inc.	0M
ZhuZhou QianJin Pharmaceutical Co.,Ltd	0M
Wockhardt Limited	0M
Chong Kun Dang Pharmaceutical Corp.	0.1M
Eris Lifesciences Limited	0M
Shenzhen Kangtai Biological Products Co., Ltd.	0M
Takeda Pharmaceutical Company Limited	0M
Medical Developments International Limited	0M
Alembic Pharmaceuticals Limited	0M
Hanmi Pharm. Co., Ltd.	0.3M

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 竞争者名单

主要竞争对手